Clinical Trials
18 trialsNCT04840602 2026-06-03
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06561347 2026-03-31
ZEBRA
Massachusetts General Hospital
Phase 2 Recruiting
NCT07474961 2026-03-16
BLOOD-dose
Rigshospitalet, Denmark
Phase 4 Not yet recruiting
NCT05640102 2026-03-04
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
BeOne Medicines
Recruiting
NCT04463953 2026-02-11
Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Completed
NCT04116437 2026-01-28
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
BeOne Medicines
Phase 2 Completed
NCT06441214 2026-01-05
Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.
Fondazione Italiana Linfomi - ETS
Active not recruiting
NCT05952037 2026-01-02
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
BeOne Medicines
Phase 2 Active not recruiting
NCT07169331 2025-12-19
A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia
BeOne Medicines
Phase 4 Recruiting
NCT06547866 2025-11-26
WAZABI
French Innovative Leukemia Organisation
Phase 2 Not yet recruiting
NCT04172246 2025-11-21
Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies
BeOne Medicines
Phase 1/2 Completed
NCT05326308 2025-09-23
ARIADNE
iOMEDICO AG
Recruiting
NCT06942507 2025-04-30
BRZ-WM
Peking Union Medical College Hospital
Phase NA Not yet recruiting
NCT03053440 2024-10-26
ASPEN
BeiGene
Phase 3 Completed
NCT03332173 2024-10-26
Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)
BeiGene
Phase 2 Completed
NCT04052854 2024-10-23
A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies
BeiGene
No longer available
NCT05914662 2024-08-28
ZBR
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT05979948 2023-09-14
CZ-WM01
Shanghai Changzheng Hospital
Phase 2 Unknown